Many pharmaceutical companies understand that closing care disparities is also good for business. However, many do not know ‘what good looks like’. Our study defines a Health Inequity Treatment Index (HITI) to quantify disparities between groups of patients receiving medicines. The HITI can be used within and across therapeutic areas to help set tangible and practical health equity goals.